<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02718859</url>
  </required_header>
  <id_info>
    <org_study_id>NK-pancre</org_study_id>
    <nct_id>NCT02718859</nct_id>
  </id_info>
  <brief_title>Combination of Irreversible Electroporation and NK Immunotherapy for Advanced Pancreatic Cancer</brief_title>
  <official_title>Study of the Combined Therapy of Irreversible Electroporation（IRE） and Nature Killer (NK) Cells for Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fuda Cancer Hospital, Guangzhou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shenzhen Hank Bioengineering Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fuda Cancer Hospital, Guangzhou</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of the combined therapy
      using irreversible electroporation（IRE）and nature killer(NK) cells for advanced pancreatic
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      By enrolling patients with pancreatic cancer adapted to enrolled criteria, this study will
      document for the first time the safety and the short and long term efficacy of the combined
      therapy using irreversible electroporation（IRE）and nature killer（NK） cells for advanced
      pancreatic cancer.

      The efficacy will be evaluated according to relief degree,progress free survival(PFS) and
      overall survival(OS).

      The safety will be evaluated by statistics of adverse reaction
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relief degree</measure>
    <time_frame>1 year</time_frame>
    <description>It will be evaluated by the Response Evaluation Criteria in Solid Tumors（RECIST）</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progress free survival（PFS）</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival（OS）</measure>
    <time_frame>3 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>irreversible electroporation (IRE)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Advanced pancreatic cancer patients received only irreversible electroporation (IRE) without immunotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IRE &amp; NK cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Advanced pancreatic cancer patients received both irreversible electroporation (IRE ) and immunotherapy of nature killer(NK) cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NK cells</intervention_name>
    <description>The pancreatic cancer patients will receive nature killer(NK) cells infusions,qd</description>
    <arm_group_label>IRE &amp; NK cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>irreversible electroporation (IRE )</intervention_name>
    <description>The pancreatic cancer patients will receive the therapy of irreversible electroporation (IRE )</description>
    <arm_group_label>irreversible electroporation (IRE)</arm_group_label>
    <arm_group_label>IRE &amp; NK cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age:18-80

          2. Diagnosis：advanced and active pancreatic cancer

          3. The tumour is measurable

          4. Eastern Cooperative Oncology Group(ECOG) score：0~2；3 but has no relationship with
             tumour

          5. Vital organ function is normal:

             total bilirubin(TB) &lt;68μmol/L aspartate aminotransferase(AST)&lt;90 IU/L Cre&lt;353μmol/L
             white blood cell count(WBC)&lt;9×10^9/L,when WBC is close to or even greater than
             9×10^9/L，the recommended dose should be halved platelet count(PLT)&gt;80×10^9/L Red blood
             cell specific volume(HCT)&gt;0.20 Non severe viral or bacterial infection

          6. Non pregnant and lactating patients

          7. Non allergic reactions to biological products

          8. Informed and consent

        Exclusion Criteria:

          1. Patients with cardiac pacemaker

          2. Patients with severe cardiac and pulmonary dysfunction

          3. Patients that the researchers do not think fit into the group,including patients
             failed in compliance assessment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lizhi Niu, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Fuda Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Huimin Tao, PhD</last_name>
    <phone>+86-18927563958</phone>
    <email>747064551@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jibing Chen, PhD</last_name>
    <phone>+86-18903068207</phone>
    <email>jibingchen398@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Central laboratory in Fuda cancer hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jibing Chen, PhD</last_name>
      <phone>+86-18903068207</phone>
      <email>jibingchen398@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2016</study_first_submitted>
  <study_first_submitted_qc>March 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2016</study_first_posted>
  <last_update_submitted>July 16, 2016</last_update_submitted>
  <last_update_submitted_qc>July 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>advanced pancreatic cancer</keyword>
  <keyword>nature killer cell</keyword>
  <keyword>irreversible electroporation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

